Offc Action Outgoing

KINISOQUIN

Quercis Pharma AG

U.S. Trademark Application Serial No. 88836223 - KINISOQUIN - N/A

To: Quercis Pharma AG (summerfv@pepperlaw.com)
Subject: U.S. Trademark Application Serial No. 88836223 - KINISOQUIN - N/A
Sent: July 30, 2020 11:06:05 AM
Sent As: ecom130@uspto.gov
Attachments:

United States Patent and Trademark Office (USPTO)

Office Action (Official Letter) About Applicant’s Trademark Application

 

U.S. Application Serial No. 88836223

 

Mark:  KINISOQUIN

 

 

 

 

Correspondence Address: 

VICTORIA D SUMMERFIELD

PEPPER HAMILTON LLP

501 GRANT STREET SUITE 300

PITTSBURGH, PA 15219

 

 

 

Applicant:  Quercis Pharma AG

 

 

 

Reference/Docket No. N/A

 

Correspondence Email Address: 

 summerfv@pepperlaw.com

 

 

 

NONFINAL OFFICE ACTION

 

The USPTO must receive applicant’s response to this letter within six months of the issue date below or the application will be abandoned.  Respond using the Trademark Electronic Application System (TEAS).  A link to the appropriate TEAS response form appears at the end of this Office action. 

 

 

Issue date:  July 30, 2020

 

This Office Action supersedes the previous Office Action dated 7/17/2020 in which the statement regarding conflicting marks below was inadvertently omitted. 

 

 The referenced application has been reviewed by the assigned trademark examining attorney.  Applicant must respond timely and completely to the issue(s) below.  15 U.S.C. §1062(b); 37 C.F.R. §§2.62, 2.65(a); TMEP §§711, 718.03.

 

The trademark examining attorney searched the USPTO database of registered and pending marks and found no conflicting marks that would bar registration under Trademark Act Section 2(d).  15 U.S.C. §1052(d); TMEP §704.02.

 

SUMMARY OF ISSUES:

·       Identification of goods requirement

·       Translation requirement

 

PROCEDURAL ISSUES

 

Identification of Goods Requirement

 

International Class 005: Applicant has identified the goods and/or services as “PHARMACEUTICAL PREPARATIONS INCLUDING THOSE FOR THE TREATMENT OF THROMBOSIS, SICKLE CELL DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, PANCREATIC CANCER, OVARIAN CANCER, EBOLA VIRUS AND COVID-19.”

 

The wording “including” in the identification of goods is indefinite and must be deleted and replaced with a definite term, such as “namely,” “consisting of,” “particularly,” or “in particular.” See 37 C.F.R. §2.32(a)(6); TMEP §§1402.01, 1402.03(a). The identification must be specific and all-inclusive. This wording is an open-ended term (e.g., “including,” “such as”) that is not acceptable because it fails to identify specific goods. See TMEP §1402.03(a).

 

The wording “pharmaceutical preparations” in the identification of goods is indefinite and must be clarified because the illness or matter being treated must be specified.  See 37 C.F.R. §2.32(a)(6); TMEP §1402.01.  Applicant must amend this wording to specify the common commercial or generic name of the goods.  See TMEP §1402.01.  If the goods have no common commercial or generic name, applicant must describe the product, its main purpose, and its intended uses.  See id.

 

Applicant may substitute the following wording, if accurate:  

 

  • Class 005:  PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF THROMBOSIS, SICKLE CELL DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, PANCREATIC CANCER, OVARIAN CANCER, EBOLA VIRUS, AND COVID-19 

 

Applicant’s goods and/or services may be clarified or limited, but may not be expanded beyond those originally itemized in the application or as acceptably amended.  See 37 C.F.R. §2.71(a); TMEP §1402.06.  Applicant may clarify or limit the identification by inserting qualifying language or deleting items to result in a more specific identification; however, applicant may not substitute different goods and/or services or add goods and/or services not found or encompassed by those in the original application or as acceptably amended.  See TMEP §1402.06(a)-(b).  The scope of the goods and/or services sets the outer limit for any changes to the identification and is generally determined by the ordinary meaning of the wording in the identification.  TMEP §§1402.06(b), 1402.07(a)-(b).  Any acceptable changes to the goods and/or services will further limit scope, and once goods and/or services are deleted, they are not permitted to be reinserted.  TMEP §1402.07(e). 

 

For assistance with identifying and classifying goods and services in trademark applications, please see the USPTO’s online searchable U.S. Acceptable Identification of Goods and Services Manual.  See TMEP §1402.04.

 

English Translation Requirement

 

Applicant must submit an English translation of all foreign wording in the mark.  37 C.F.R. §2.32(a)(9); see TMEP §809.  In the present case, the wording “KINISOQUIN” requires translation.

 

The following translation statement is suggested: 

 

  • The English translation of “KINISOQUIN” in the mark is “{specify translation}”. 

TMEP §809.03.

 

If this term has no meaning in a foreign language, applicant should provide the following statement: 

  • The wording “KINISOQUIN” has no meaning in a foreign language.” 

Id.

 

RESPONSE GUIDELINES

 

Applicant should include the following information on all correspondence with the Office:  (1) the name and law office number of the trademark examining attorney, (2) the serial number and filing date of the application, (3) the date of issuance of this Office action, (4) applicant’s name, address, telephone number and e-mail address (if applicable), and (5) the mark.  37 C.F.R. §2.194(b)(1); TMEP §302.03(a).

 

Please call or email the assigned trademark examining attorney with questions about this Office action.  Although an examining attorney cannot provide legal advice, the examining attorney can provide additional explanation about the refusal(s) and/or requirement(s) in this Office action.  See TMEP §§705.02, 709.06. 

 

The USPTO does not accept emails as responses to Office actions; however, emails can be used for informal communications and are included in the application record.  See 37 C.F.R. §§2.62(c), 2.191; TMEP §§304.01-.02, 709.04-.05. 

 

 

How to respond.  Click to file a response to this nonfinal Office action.    

 

 

/mvaghani/

Mayur Vaghani

Trademark Examining Attorney

Law Office 130

Phone: (571) 272-1615

mayur.vaghani@uspto.gov

 

 

RESPONSE GUIDANCE

  • Missing the response deadline to this letter will cause the application to abandon.  A response or notice of appeal must be received by the USPTO before midnight Eastern Time of the last day of the response period.  TEAS and ESTTA maintenance or unforeseen circumstances could affect an applicant’s ability to timely respond.  

 

 

 

U.S. Trademark Application Serial No. 88836223 - KINISOQUIN - N/A

To: Quercis Pharma AG (summerfv@pepperlaw.com)
Subject: U.S. Trademark Application Serial No. 88836223 - KINISOQUIN - N/A
Sent: July 30, 2020 11:06:07 AM
Sent As: ecom130@uspto.gov
Attachments:

United States Patent and Trademark Office (USPTO)

 

USPTO OFFICIAL NOTICE

 

Office Action (Official Letter) has issued

on July 30, 2020 for

U.S. Trademark Application Serial No. 88836223

 

Your trademark application has been reviewed by a trademark examining attorney.  As part of that review, the assigned attorney has issued an official letter that you must respond to by the specified deadline or your application will be abandoned.  Please follow the steps below.

 

(1)  Read the official letter.

 

(2)  Direct questions about the contents of the Office action to the assigned attorney below. 

 

 

/mvaghani/

Mayur Vaghani

Trademark Examining Attorney

Law Office 130

Phone: (571) 272-1615

mayur.vaghani@uspto.gov

 

Direct questions about navigating USPTO electronic forms, the USPTO website, the application process, the status of your application, and/or whether there are outstanding deadlines or documents related to your file to the Trademark Assistance Center (TAC).

 

(3)  Respond within 6 months (or earlier, if required in the Office action) from July 30, 2020, using the Trademark Electronic Application System (TEAS).  The response must be received by the USPTO before midnight Eastern Time of the last day of the response period.  See the Office action for more information about how to respond

 

 

 

GENERAL GUIDANCE

·       Check the status of your application periodically in the Trademark Status & Document Retrieval (TSDR) database to avoid missing critical deadlines.

 

·       Update your correspondence email address, if needed, to ensure you receive important USPTO notices about your application.

 

·       Beware of misleading notices sent by private companies about your application.  Private companies not associated with the USPTO use public information available in trademark registrations to mail and email trademark-related offers and notices – most of which require fees.  All official USPTO correspondence will only be emailed from the domain “@uspto.gov.”

 

 

 


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed